Netherlands Archives

News and Trends 23 Sep 2022

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed. We also have our weekly chat with global […]

September 23, 2022 - 4 minutesmins - By Jim Cornall

glioblastoma oncolytic virus transgene 2

News and Trends 20 Sep 2022

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M), including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure is the lead coordinator of […]

September 20, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Fooditive creating bee-free honey using precision fermentation biotech

Dutch plant-based ingredients company Fooditive is scaling up existing products and introducing the latest developments: LowSalt & Bee-free-Honey. “We feel like the next chapter of this journey has just begun. With the support from our shareholders, clients, partners and our team we are focused to increase our impact and make a fundamental change in the […]

September 20, 2022 - 3 minutesmins - By Jim Cornall

Prothena, Parkinsons Disease, neurons, neurological diseases

News and Trends 15 Sep 2022

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds

Wageningen University & Research (WUR), and its spinoff Scope Biosciences, have received a grant of €150,000 ($152,000) from the European Research Council (ERC). The grant is to further research and enhance the diagnostic technology ScopeDx. This is based on CRISPR-Cas technology. Uniquely, this technology is able to quickly and accurately recognize viral or bacterial RNA. […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Synaffix and Emergence in $360M technology platform deal to develop ADCs

Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […]

September 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

Pleco Therapeutics raises €17.3M to develop AML product

Pleco Therapeutics BV, a specialty biopharmaceutical company in the Netherlands developing novel treatments designed to detoxify the cancer micro-environment has raised total funds of €17.3 million ($17.2 million) in series A financing. The funds will be used to complete development of, and to commercialize, the company’s novel lead Plecoid product, PTX-061, to improve the effectiveness […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

argenx secures European Commission approval for generalized myasthenia gravis treatment

Dutch immunology company argenx says the European Commission (EC) has granted marketing authorization for VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The approval is applicable to all 27 European Union (EU) Member States plus Iceland, […]

August 12, 2022 - 3 minutesmins - By Jim Cornall

In Depth 3 Aug 2022

The biggest European biotech investments in July 2022

The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […]

August 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 2 Aug 2022

New monkeypox tracing method can analyze multiple samples and quickly detect virus strains

Dutch company Molecular Biology Systems (MBS), in collaboration with Amsterdam University Medical Center, and researchers from the Danish Rigshospitalet, has developed a fast typing method to trace monkeypox. The new method, NextGenPCR, not only detects strains of the virus quickly, it allows for analysis of multiple samples simultaneously. This way, the inventors say, genetic characterization […]

August 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Glycostem and medac sign deal on AML and MM product

Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

Pleco Therapeutics expands into U.S. and names president

Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us